Inhibikase Therapeutics, Inc. Balance Sheet
IKT|4 years of annual SEC 10-K data (FY2021-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
Inhibikase Therapeutics, Inc. had $99M in total assets and $11M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Cash & Equivalents | $56.5M | $9.2M | $7.2M | - |
| Current Assets | $98.5M | $14.2M | $24.4M | - |
| PP&E (Net) | $47.1K | $73.4K | $236.5K | - |
| Total Assets | $98.6M | $14.5M | $24.9M | $42.5M |
| Current Liabilities | $3.7M | $3.4M | $3.7M | $4.1M |
| Shareholders' Equity | $11.0M | $21.0M | $38.4M | $9.8M |